REFERENCES
1. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol 2022;7:851-61.
2. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021;70:962-9.
3. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. IJMS 2020;21:5888.
4. Konyn P, Ahmed A, Kim D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin Mol Hepatol 2023;29:S43-57.
5. Kim D, Adejumo AC, Yoo ER, et al. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology 2019;157:1055-66.e11.
6. Duell PB, Welty FK, Miller M, et al. on behalf of the American Heart Association Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the american heart association. ATVB 2022;42:e168-85.
7. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:903-13.
8. Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroen Hepat 2017;29:e28-35.
9. Wong MYZ, Yap JJL, Sultana R, Cheah M, Goh GBB, Yeo KK. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. Open Heart 2021;8:e001850.
10. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2019;140:e596-646.
11. Yi M, Peng W, Teng F, Kong Q, Chen Z. The role of noninvasive scoring systems for predicting cardiovascular disease risk in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroen Hepat 2022;34:1277-84.
12. Jamalinia M, Zare F, Noorizadeh K, Bagheri lankarani K. Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther 2024;59:445-58.
13. Jamalinia M, Zare F, Lankarani KB. Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2023;58:384-94.
14. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9.
15. Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
16. Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol 2021;19:2138- 47.e10.
17. Sung K, Yoo TK, Lee MY, Byrne CD, Zheng M, Targher G. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study. ATVB 2023;43:482-91.
18. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-56.
19. Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. eClinicalMedicine 2023;65:102292.
20. Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism 2024; doi: 10.1016/j.metabol.2024.155800.
21. Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States. Aliment Pharmacol Ther 2024;60:33-42.
22. Tamaki N, Kimura T, Wakabayashi S, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther 2024;60:61-9.
23. Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States. J Hepatol 2024;80:e79-81.
24. Ng CH, Chan KE, Ou KQ, et al. IDDF2022-ABS-0132 Mafld and nafld in lean individuals. A prospective analysis of 12,505 lean individuals. Gut 2022;71:A50.
25. De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J Hepatol 2024;80:e61-2.
26. Ramírez-mejía MM, Jiménez-gutiérrez C, Eslam M, George J, Méndez-sánchez N. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int 2024;18:168-78.
27. Wijarnpreecha K, Li F, Lundin SK, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther 2023;57:1014-27.
28. Arvind A, Henson JB, Osganian SA, et al. Risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease. Hepatol Commun 2022;6:309-19.
29. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739-52.
30. Nso N, Mergen D, Ikram M, et al. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis. Curr Prob Cardiology 2024;49:102569.
31. Kang MK, Song J, Loomba R, Park S, Tak W, Kweon Y, et al. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification. Res Sq 2024;rs.3:rs-3979461.
32. Chan KE, Ong EYH, Chung CH, et al. Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies. Clin Gastroenterol H 2024;22:488-98.e14.
33. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut ;2024:73:691-702.
34. Durak H, Çetin M, Emlek N, et al. FIB-4 liver fibrosis index correlates with aortic valve sclerosis in non-alcoholic population. Echocardiography 2024;41:e15732.
35. Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 2022;24:28-43.
36. Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2018;15:425-39.
37. Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: a mendelian randomization study. Hepatology 2023;77:230-8.
38. Kumar J, Mohsin S, Hasan M, et al. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - a systematic review and meta-analysis. Clin Res Hepatol Gas 2024;48:102261.
39. Wang G, Huang Y, Yang H, Lin H, Zhou S, Qian J. Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis. Surg Obes Relat Dis 2023;19:717-26.
40. Solomon A, Negrea MO, Cipăian CR, et al. Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center cross-sectional study. Healthcare 2023;11:2696.
41. Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 2018;68:335-52.
42. Brunner KT, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int 2020;40:1339-43.
43. Brunner KT, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Increasing liver fat is associated with incident cardiovascular risk factors. Clin Gastroenterol H 2020;18:1884-6.
44. Srinivas AN, Suresh D, Santhekadur PK, Suvarna D, Kumar DP. Extracellular vesicles as inflammatory drivers in NAFLD. Front Immunol 2021;11:627424.
45. Chandrasekharan K, Alazawi W. Genetics of non-alcoholic fatty liver and cardiovascular disease: implications for therapy? Front Pharmacol 2020;10:1413.
46. Petermann-rocha F, Wirth MD, Boonpor J, et al. Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants. BMC Med 2023;21:123.
47. Khan A, Ding Z, Ishaq M, et al. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: recent updates. Int J Biol Sci 2021;17:818-33.
48. Lonardo A, Singal A, Osna N, Kharbanda KK. Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. Metab Target Organ Damage 2022;2:12.
49. Mauvais-jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. The Lancet 2020;396:565-82.
50. Desai R, Alvi AT, Vasavada A, et al. Sex and racial disparities in non-alcoholic fatty liver disease-related cardiovascular events: national inpatient sample analysis (2019). World J Cardiol 2024;16:137-48.
51. Kammerlander AA, Lyass A, Mahoney TF, et al. Sex differences in the associations of visceral adipose tissue and cardiometabolic and cardiovascular disease risk: the Framingham heart study. JAHA 2021;10:e019968.
52. Polman R, Hurst JR, Uysal OF, Mandal S, Linz D, Simons S. Cardiovascular disease and risk in COPD: a state of the art review. Expert Rev Cardiovasc Ther 2024;22:177-91.
53. Lonardo A, Beghe B, Fabbri LM. Chronic obstructive pulmonary disease (COPD) and metabolic fatty liver syndromes: a dangerous but neglected liaison. Metab Target Organ Damage 2022;2:6.
54. Viglino D, Plazanet A, Bailly S, et al. Impact of non-alcoholic fatty liver disease on long-term cardiovascular events and death in chronic obstructive pulmonary disease. Sci Rep 2018;8:16559.
55. Lonardo A. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review. Metab Target Organ Damage 2024;4:16.
56. Miyamori D, Tanaka M, Sato T, et al. Coexistence of metabolic dysfunction-associated fatty liver disease and chronic kidney disease is a more potent risk factor for ischemic heart disease. JAHA 2023;12:e030269.
57. Loria P, Adinolfi LE, Bellentani S, et al. NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian association for the study of the liver (AISF) expert committee. Dig Liver Dis 2010;42:272-82.
58. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263-71.
59. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602.
60. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
61. Spahillari A, Mukamal K, Defilippi C, et al. The association of lean and fat mass with all-cause mortality in older adults: the cardiovascular health study. Nutr Metab Cardiovas 2016;26:1039-47.
62. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016;65:589-600.
63. Stefan N, Lonardo A, Targher G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat Rev Gastroenterol Hepatol 2024;21:136-7.
64. Li M, Wang H, Zhang X, Cai J, Li H. NAFLD: an emerging causal factor for cardiovascular disease. Physiology 2023;38:255-65.
65. Li W, Sheridan D, Mcpherson S, et al. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022. JHEP Reports 2023;5:100897.
66. Driessen S, Francque SM, Anker SD, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology :Online ahead of print.
67. Aller R, Fernández-rodríguez C, lo Iacono O, et al. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterología y Hepatología 2018;41:328-49.
68. Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
69. Rinella ME, Neuschwander-tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023;77:1797-835.
70. Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings. Endocrine Practice 2022;28:528-62.
71. Visseren FLJ, Mach F, Smulders YM, et al. ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-337.
72. Ren Z, Wesselius A, Stehouwer CD, Brouwers MC. Cardiovascular implications of metabolic dysfunction-associated fatty liver disease. Endocrin Metab Clin 2023;52:459-68.
73. Chiang CH, Huang CC, Chan WL, Chen JW, Leu HB. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem 2010;43:1399-404.
74. Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroent 2015;9:629-50.
75. Ichikawa K, Miyoshi T, Osawa K, et al. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study. Cardiovasc Diabetol 2021;20:8.
76. Kweon Y, Ko H, Kim A, et al. Prediction of cardiovascular risk using nonalcoholic fatty liver disease scoring systems. Healthcare 2021;9:899.
77. Tsou M, Chen J. Gender-based association of coronary artery calcification and framingham risk score with non-alcoholic fatty liver disease and abdominal obesity in taiwanese adults, a cross-sectional study. Front Cardiovasc Med 2022;9:803967.
78. Zhou H, Zhang C, Ni J, Han X. Prevalence of cardiovascular risk factors in non-menopausal and postmenopausal inpatients with type 2 diabetes mellitus in China. BMC Endocr Disord 2019:19.
80. Ballestri S, Mantovani A, Girolamo MD, Baldelli E, Capitelli M, Lonardo A. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. Metab Target Organ Damage 2023;3:1.
81. Kim Y, Han E, Lee JS, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut and Liver 2022;16:290-9.
82. Han E, Lee Y, Kim YD, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol 2020;115:584-95.
83. Zhang P, Dong X, Zhang W, et al. Metabolic-associated fatty liver disease and the risk of cardiovascular disease. Clin Res Hepatol Gas 2023;47:102063.
84. Chun HS, Lee M, Lee JS, et al. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Liver Int 2023;43:608-25.
85. Semmler G, Balcar L, Wernly S, et al. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease. Front Endocrinol 2023;14:1244405.
86. Martínez-arranz I, Bruzzone C, Noureddin M, et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology 2022;76:1121-34.
87. Lauridsen BK, Stender S, Kristensen TS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279013 individuals. Eur Heart J 2018;39:385-93.
88. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The F ramingham risk score and heart disease in nonalcoholic fatty liver disease . Liver Int 2012;32:945-50.
89. Golabi P, Fukui N, Paik J, Sayiner M, Mishra A, Younossi ZM. Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease. Hepatol Commun 2019;3:1050-60.
90. Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med 2024;122:28-34.
91. Lonardo A. Renaming NAFLD to MAFLD: could the LDE system assist in this transition? JCM 2021;10:492.
92. Thiele M, Kamath PS, Graupera I, et al. Screening for liver fibrosis: lessons from colorectal and lung cancer screening. Nat Rev Gastroenterol Hepatol ; doi: 10.1038/s41575-024-00907-2.
93. Niederseer D, Wernly S, Bachmayer S, et al. Diagnosis of non-alcoholic fatty liver disease (NAFLD) is independently associated with cardiovascular risk in a large austrian screening cohort. JCM 2020;9:1065.
94. Simon TG, Kartoun U, Zheng H, et al. Model for end-stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease. Hepatol Commun 2017;1:429-38.
95. Mangla N, Ajmera VH, Caussy C, et al. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes. Clin Gastroenterol H 2020;18:744-6.e1.
96. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021;161:1657-69.
97. Sterling RK, Patel K, Duarte-rojo A, et al. AASLD practice guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology ; doi: 10.1097/hep.0000000000000845.
98. Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:728-36.
99. Vilar-gomez E, Calzadilla-bertot L, Wai-sun Wong V, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018;155:443-457.e17.
100. Cardoso CRL, Villela-nogueira CA, Leite NC, Salles GF. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. Cardiovasc Diabetol 2021;20:193.
101. Shili-masmoudi S, Wong GL, Hiriart J, et al. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 2020;40:581-9.
102. Arai T, Atsukawa M, Tsubota A, et al. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep 2021;11:15938.
103. Arai T, Atsukawa M, Tsubota A, et al. Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. PLoS ONE 2019;14:e0224184.
104. Sonaglioni A, Cerini F, Nicolosi GL, Lombardo M, Rumi MG, Viganò M. Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients. Eur J Gastroen Hepat 2022;34:707-16.
105. Anstee QM, Berentzen TL, Nitze LM, et al. Prognostic utility of fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur 2024;36:100780.
106. Baratta F, Pastori D, Angelico F, et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol H 2020;18:2324-31.e4.
107. Shao C, Ye J, Li F, et al. Early predictors of cardiovascular disease risk in nonalcoholic fatty liver disease: non-obese versus obese patients. Dig Dis Sci 2020;65:1850-60.
108. Wu T, Ye J, Shao C, et al. The ability of lipoprotein (a) level to predict early carotid atherosclerosis is impaired in patients with advanced liver fibrosis related to metabolic-associated fatty liver disease. Clin Transl Gastroenterol 2022;13:e00504.
109. You SC, Kim KJ, Kim SU, et al. Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. J of Gastro and Hepatol 2015;30:1536-42.
110. Yu X, Song X, Tong Y, Wu L, Song Z. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. Medicine 2020;99:e23360.
111. Hanafy AS, Abd-Elsalam S, Ahmed AF, Dawoud MM. Multifocal fatty liver disease, insulin resistance and carotid atherosclerosis: exploring the interrelated relationship. J Ultrason 2018;18:302-9.
112. Kim H, Koo BK, Joo SK, Kim W. Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease. Hepatol Int 2020;14:1048-56.
113. Park JG, Jung J, Verma KK, et al. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2021;53:1030-7.
114. Tan EC, Tai MS, Chan W, Mahadeva S. Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community. JGH Open 2019;3:117-25.
115. Tamaki N, Higuchi M, Kurosaki M, et al. Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol H 2022;20:1171-1173.e2.
116. Mózes FE, Lee JA, Selvaraj EA, et al. LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022;71:1006-19.
117. Han S, Choi M, Lee B, et al. Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gut and Liver 2022;16:952-63.
118. Younossi ZM, Stepanova M, Felix S, et al. The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2023;57:1417-22.
119. Gosalia D, Ratziu V, Stanicic F, et al. Accuracy of noninvasive diagnostic tests for the detection of significant and advanced fibrosis stages in nonalcoholic fatty liver disease: a systematic literature review of the US studies. Diagnostics 2022;12:2608.
120. Golabi P, Paik JM, Harring M, Younossi E, Kabbara K, Younossi ZM. Prevalence of high and moderate risk nonalcoholic fatty liver disease among adults in the United States, 1999-2016. Clin Gastroenterol H 2022;20:2838-2847.e7.
121. Pisto P, Santaniemi M, Bloigu R, Ukkola O, Kesäniemi YA. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open 2014;4:e004973.
122. Kim K, Hong S, Han K, Park C. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ ; doi: 10.1136/bmj-2023-076388.
123. Yoshioka Y, Hashimoto E, Yatsuji S, et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol 2004;39:1215-8.
124. van der Poorten D, Samer CF, Ramezani-moghadam M, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology 2013;57:2180-8.
125. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. the LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1209-22.
126. Lonardo A, Ballestri S, Bedogni G, Bellentani S, Tiribelli C. The fatty liver index (FLI) 15 years later: a reappraisal. Metab Target Organ Damage 2021;1:10.
127. Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 2017;152:598-607.e2.
128. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082-90.
129. Ballestri S, Mantovani A, Byrne CD, Lonardo A, Targher G. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. Metab Target Organ Damage 2021;1:7.
130. Allan PL, Mowbray PI, Lee AJ, Fowkes FGR. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease: the Edinburgh artery study. Stroke 1997;28:348-53.
131. Bakhshi H, Ambale-venkatesh B, Yang X, et al. Progression of Coronary artery calcium and incident heart failure: the multi-ethnic study of atherosclerosis. JAHA 2017;6:e005253.
132. Fuchs A, Kühl JT, Sigvardsen PE, et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a danish cohort: a prospective observational cohort study. Ann Intern Med 2023;176:433-42.
133. Geurts S, Brunborg C, Papageorgiou G, Ikram MA, Kavousi M. Subclinical measures of peripheral atherosclerosis and the risk of new-onset atrial fibrillation in the general population: the Rotterdam study. JAHA 2022;11:e023967.
